January 12, 2018 09:03 AM EST
Peer Review

Why did Abl­ynx board chair­man Pe­ter Fell­ner re­sign in wake of Novo's buy­out of­fer?; Am­gen vet Richard Paul­son tapped to run Ipsen North Amer­i­ca

Amber Tong

→ What’s hap­pen­ing at Abl­ynx? On the same day Dan­ish bio­phar­ma No­vo Nordisk $NVO went pub­lic with its lat­est, $3.1 bil­lion of­fer to buy …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

A service from the Financial Times